Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Image-guided Targeted Doxorubicin Delivery With Hyperthermia to Optimize Loco-regional Control in Breast Cancer. Phase I Feasibility Study of Hifu-Induced Hyperthermia, LTLD and Cyclophosphamide for Metastatic Breast Cancer

NCT03749850 is registered in ClinicalTrials.gov with UMC Utrecht as lead sponsor.

NCT NCT03749850
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03749850 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Image-guided Targeted Doxorubicin Delivery With Hyperthermia to Optimize Loco-regional Control in Breast Cancer. Phase I Feasibility Study of Hifu-Induced Hyperthermia, LTLD and Cyclophosphamide for Metastatic Breast Cancer
Lead sponsor
UMC Utrecht
Phase
Phase 1
Overall status
Unknown status
Start date
March 31, 2021
Completion date
November 30, 2022
Enrollment
12 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

adenocarcinoma breast, breast cancer, breast neoplasms, invasive ductal breast cancer, invasive ductal carcinoma of female breast, metastatic breast cancer, metastatic cancer, stage iv breast cancer